

physicians specializing in addiction medicine of whether buprenorphine as prescribed and distributed under the Waiver Program is a useful tool in the treatment of substance abuse, and whether there are any negative consequences associated with it. The survey will also assess whether there are early indications of limitations to the availability of the medication, related to factors such as geographic location, type

of medical practice, patient population, or ability to pay. Physicians who do not respond after two mailings will receive a brief postcard to complete.

Results from this survey will influence the focus and content of two additional proposed surveys to be fielded later in 2003. A second survey will focus on the clinical practice and perceived effectiveness of buprenorphine among physicians who

are actively prescribing the medication. A third survey of patients who have received buprenorphine will assess its effectiveness and availability from the patients' point of view. A separate **Federal Register** notice will be published for each of these surveys. The estimated response burden for the first survey of physicians is summarized below.

Addiction physicians	Number of respondents	Responses/ respondent	Hours per response	Total hour burden
Physician Survey	957	1	.33	316
Followup Postcard	335	1	.017	6
Total	957			322

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Herron Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; because of mail delays, it is recommended that comments be sent by fax to: (202) 395-6974.

Dated: May 27, 2003.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 03-13789 Filed 6-2-03; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at the following Web sites: <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersch or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, (414) 328-7840/(800) 877-7016, (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, (585) 429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, (901) 794-5770/(888) 290-1150.
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, (615) 255-2400.
Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, (513) 585-6870, (Formerly: Jewish Hospital of Cincinnati, Inc.).
Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, (501) 202-2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, (800) 445-6917.
Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, (800) 876-3652 / (417) 269-3093, (Formerly: Cox Medical Centers).
Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, (239) 561-8200 / (800) 735-5416.
Doctors Laboratory, Inc., PO Box 2658, 2906 Julia Dr., Valdosta, GA 31602, (912) 244-4468.
DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, (206) 386-2661 / (800) 898-0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).
DrugScan, Inc., PO Box 2969, 1119 Mearns Rd., Warminster, PA 18974, (215) 674-9310.

Dynacare Kasper Medical Laboratories,*
10150-102 Street, Suite 200,
Edmonton, Alberta, Canada T5J 5E2,
(780) 451-3702 / (800) 661-9876.

ElSohly Laboratories, Inc., 5 Industrial
Park Dr., Oxford, MS 38655, (662)
236-2609.

Express Analytical Labs, 3405 7th
Avenue, Suite 106, Marion, IA 52302,
(319) 377-0500.

Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall St.,
London, ONT, Canada N6A 1P4, (519)
679-1630.

General Medical Laboratories, 36 South
Brooks St., Madison, WI 53715, (608)
267-6225.

Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053, (504)
361-8989 / (800) 433-3823,
(Formerly: Laboratory Specialists,
Inc.).

LabOne, Inc., 10101 Renner Blvd.,
Lenexa, KS 66219, (913) 888-3927 /
(800) 873-8845, (Formerly: Center for
Laboratory Services, a Division of
LabOne, Inc.).

Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, (713) 856-8288 /
(800) 800-2387.

Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, (908) 526-2400 / (800) 437-
4986, (Formerly: Roche Biomedical
Laboratories, Inc.).

Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
(919) 572-6900 / (800) 833-3984,
(Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).

Laboratory Corporation of America
Holdings, 10788 Roselle Street, San
Diego, CA 92121, (800) 882-7272,
(Formerly: Poisonlab, Inc.).

Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, (715)
389-3734 / (800) 331-3734.

MAXXAM Analytics Inc.,* 5540
McAdam Rd., Mississauga, ON,
Canada L4Z 1P1, (905) 890-2555,
(Formerly: NOVAMANN (Ontario)
Inc.).

MedTox Laboratories, Inc., 402 W.
County Rd. D, St. Paul, MN 55112,
(651) 636-7466 / (800) 832-3244.

MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, (503) 413-5295 / (800) 950-
5295.

Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, Minnesota 55417, (612)
725-2088.

National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, (661) 322-4250 / (800) 350-
3515.

Northwest Drug Testing, a division of
NWT Inc., 1141 E. 3900 South, Salt
Lake City, UT 84124, (801) 293-2300
/ (800) 322-3361, (Formerly: NWT
Drug Testing, NorthWest Toxicology,
Inc.).

One Source Toxicology Laboratory, Inc.,
1705 Center Street, Deer Park, TX
77536, (713) 920-2559, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).

Oregon Medical Laboratories, PO Box
972, 722 East 11th Ave., Eugene, OR
97440-0972, (541) 687-2134.

Pacific Toxicology Laboratories, 9348
De Soto Ave., Chatsworth, CA 91311,
(800) 328-6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).

Pathology Associates Medical
Laboratories, 110 West Cliff Drive,
Spokane, WA 99204, (509) 755-8991
/ (800) 541-7891x8991.

PharmChem Laboratories, Inc., 4600 N.
Beach, Haltom City, TX 76137, (817)
605-5300, (Formerly: PharmChem
Laboratories, Inc., Texas Division;
Harris Medical Laboratory).

Physicians Reference Laboratory, 7800
West 110th St., Overland Park, KS
66210, (913) 339-0372 / (800) 821-
3627.

Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
(770) 452-1590/(800) 729-6432,
(Formerly: SmithKline Beecham
Clinical Laboratories, SmithKline Bio-
Science Laboratories).

Quest Diagnostics Incorporated, 4770
Regent Blvd., Irving, TX 75063, (800)
824-6152, (Moved from the Dallas
location on 03/31/01; Formerly:
SmithKline Beecham Clinical
Laboratories, SmithKline Bio-Science
Laboratories).

Quest Diagnostics Incorporated, 4230
South Burnham Ave., Suite 250, Las
Vegas, NV 89119-5412, (702) 733-
7866 / (800) 433-2750, (Formerly:
Associated Pathologists Laboratories,
Inc.).

Quest Diagnostics Incorporated, 400
Egypt Rd., Norristown, PA 19403,
(610) 631-4600 / (877) 642-2216,
(Formerly: SmithKline Beecham
Clinical Laboratories, SmithKline Bio-
Science Laboratories).

Quest Diagnostics Incorporated, 506 E.
State Pkwy., Schaumburg, IL 60173,
(800) 669-6995 / (847) 885-2010,
(Formerly: SmithKline Beecham
Clinical Laboratories, International
Toxicology Laboratories).

Quest Diagnostics Incorporated, 7600
Tyronne Ave., Van Nuys, CA 91405,
(818) 989-2520 / (800) 877-2520,
(Formerly: SmithKline Beecham
Clinical Laboratories).

Scientific Testing Laboratories, Inc., 450
Southlake Blvd., Richmond, VA
23236, (804) 378-9130.

Sciteck Clinical Laboratories, Inc., 317
Rutledge Road, Fletcher, NC 28732,
(828) 650-0409.

S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109, (505)
727-6300 / (800) 999-5227.

South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, (574) 234-4176x276.

Southwest Laboratories, 2727 W.
Baseline Rd., Tempe, AZ 85283, (602)
438-8507 / (800) 279-0027.

Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
(517) 377-0520, (Formerly: St.
Lawrence Hospital & Healthcare
System).

St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, (405) 272-
7052.

Sure-Test Laboratories, Inc., 2900 Broad
Avenue, Memphis, Tennessee 38112,
(901) 474-6028.

Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 2703 Clark Lane,
Suite B, Lower Level, Columbia, MO
65202, (573) 882-1273.

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (**Federal Register**, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 **Federal Register**, 9 June 1994, Pages 29908-29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and participate in the NLCP certification maintenance program.

Toxicology Testing Service, Inc., 5426 NW., 79th Ave., Miami, FL 33166, (305) 593-2260

US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson Street, Fort George G. Meade, MD 20755-5235, (301) 677-3714.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 03-13791 Filed 6-2-03; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2003 and Fiscal Year (FY) 2004 Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of funding availability for SAMHSA Cooperative Agreements for the Comprehensive Community Mental Health Services Program for Children and their Families.

SUMMARY: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services (CMHS) announces the availability of FY 2003 and FY 2004 funds for the cooperative agreement described below. A synopsis of this funding opportunity, as well as many other Federal government funding opportunities, is also available at the Internet site: www.fedgrants.gov.

This notice is not a complete description of the program; potential applicants must obtain a copy of the Request for Applications (RFA), including part I, Cooperative Agreements for the Comprehensive Community Mental Health Services Program for Children and their Families, part II, General Policies and Procedures Applicable to all SAMHSA Applications for Discretionary Grants and Cooperative Agreements, and the PHS 5161-1 (Rev. 7/00) application form before preparing and submitting an application.

Funding Opportunity Title: Cooperative Agreements for the Comprehensive Community Mental Health Services Program for Children and their Families—Short Title: Child Mental Health Initiative.

Funding Opportunity Number: SM 03-009.

Catalog of Federal Domestic Assistance (CFDA) Number: 93.243.

Authority: Section: part E of title V section 561 *et seq.* of the Public Health Service Act,

as amended and subject to the availability of funds.

Funding Opportunity Description: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services is accepting applications for Fiscal Year 2003 and Fiscal Year 2004 for cooperative agreements to develop systems of care that deliver effective comprehensive community mental health services for a target population of children and adolescents with serious emotional disturbance and their families. Funds will be awarded to develop community service systems for the target population, and also to fund a broad array of services delivered through those service systems. In addition, awardees will participate in a national multi-site evaluation, conducted through a separate contract, and will be encouraged to develop the capacity for continuous evaluation of their systems of care.

Eligible Applicants: Eligibility for this program is statutorily limited to public entities such as: State governments; Indian tribes or tribal organizations (as defined in section 4(b) and section 4(c) of the Indian Self-Determination and Education Assistance Act); governmental units within political subdivisions of a State such as a county, city, or town; the District of Columbia government; and the government of the territories of Guam, Commonwealth of Puerto Rico, Northern Mariana Islands, Virgin Islands, American Samoa, and Trust Territory of the Pacific Islands (now Palau, Micronesia, and the Marshall Islands). Additional eligibility requirements are listed in the full announcement.

Due Date for Applications: August 5, 2003, for FY 2003; October 15, 2003, for FY 2004.

Estimated Funding Available/Number of Awards: It is expected that approximately \$5 million will be available for about 5 awards in FY 2003 and \$5 million for about 5 awards in FY 2004. The maximum amount available in total direct and indirect costs for each year of the award will be as follows:

Year 1: \$1 million
Year 2: \$1.5 million
Year 3: \$2.5 million
Year 4: \$2 million
Year 5: \$1.5 million
Year 6: \$1 million

Actual funding levels will depend on the availability of funds. Applications with proposed budgets that exceed the maximum allowed in any year will be returned without review.

Is Cost Sharing Required: Yes. By statutory mandate, this program requires

that the applicant entity will provide, directly or through donations from public or private entities, non-Federal contributions:

- For the first, second and third fiscal years of the cooperative agreement, the awardee must provide at least \$1 for each \$3 of Federal funds;
- For the fourth fiscal year, the awardee must provide at least \$1 for each \$1 of Federal funds; and
- For the fifth and sixth fiscal year, the awardee must provide at least \$2 for each \$1 of Federal funds.

Matching resources may be in cash or in-kind, including facilities, equipment, or services, and must be derived from non-Federal sources (e.g., State or sub-State non-Federal revenues, foundation grants). Additional cost sharing information is provided in the full announcement.

Period of Support: Up to 6 years, with annual continuations depending on availability of funds and progress achieved.

How to Get Full Announcement and Application Materials: Complete application kits may be obtained from the National Mental Health Information Center, PO Box 42557, Washington, DC 20015, 800-789-2647. The PHS 5161-1 application form and the full text of the funding announcement are also available electronically via SAMHSA's World Wide Web home page: <http://www.samhsa.gov> (click on 'Grant Opportunities').

When requesting an application kit, the applicant must specify the funding opportunity title and number for which detailed information is desired. All information necessary to apply, including where to submit applications and application deadline instructions, are included in the application kit.

Contact for Additional Information: Rolando L. Santiago, Ph.D., or Diane Sondheimer, M.S., M.P.H., Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, Child, Adolescent, and Family Branch, 5600 Fishers Lane, Room 11C-16, Rockville, MD 20857, (301) 443-1333, E-mail: rsantiago@samhsa.gov or dsondhei@samhsa.gov.

Dated: May 27, 2003.

Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 03-13759 Filed 6-2-03; 8:45 am]

BILLING CODE 4160-20-P